Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00529503 · ClinicalTrials.gov registry record · Phase 2
A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL
A Phase 2 study, sponsored by Seagen.
- Terminated
- Registry status
- Phase 2
- Development phase
- 151
- Enrollment target
NCT00529503 is a Phase 2 study that was terminated before completion, run by Seagen. The registered enrollment target is 151 participants.
The verdict
NCT00529503, a Phase 2 study, was terminated before completion, sponsored by Seagen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 151 participants
- Enrollment target
Study Summary
This is a randomized trial to estimate the activity of R-ICE plus SGN-40 vs. R-ICE plus placebo in patients with DLBCL. The study will assess safety and tolerability and will measure any additional clinical benefit observed in patients receiving SGN-40.
Interventions
- DRUG placebo
- DRUG carboplatin
- DRUG etoposide
- DRUG rituximab
- DRUG SGN-40
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2007-09 |
| Est. Completion | 2011-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00529503
The ClinicalTrials.gov registry entry for NCT00529503 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 151 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which placebo is the first listed.
NCT00529503 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00529503 about?
NCT00529503 is a clinical study titled "A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL". This is a randomized trial to estimate the activity of R-ICE plus SGN-40 vs. R-ICE plus placebo in patients with DLBCL. The study will assess safety and tolerability and will measure any additional clinical benefit observed in patients receiving SGN-40.
What is the current status of trial NCT00529503?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 151 participants. The study started on 2007-09. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00529503?
The interventions under investigation include: placebo (DRUG), carboplatin (DRUG), etoposide (DRUG), rituximab (DRUG), SGN-40 (DRUG).
Who is sponsoring clinical trial NCT00529503?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.